Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. more
Time Frame | SRPT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.83% | -2.12% | -3% |
1-Month Return | 7.32% | -3.42% | -0.73% |
3-Month Return | -6.48% | -11.13% | 2.87% |
6-Month Return | -3.67% | -5.74% | 7.17% |
1-Year Return | 31.76% | 3.97% | 25.31% |
3-Year Return | 33.66% | 1.05% | 28.38% |
5-Year Return | -5.71% | 34.37% | 81.89% |
10-Year Return | 786.51% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 380.83M | 540.10M | 701.89M | 933.01M | 1.24B | [{"date":"2019-12-31","value":30.63,"profit":true},{"date":"2020-12-31","value":43.44,"profit":true},{"date":"2021-12-31","value":56.45,"profit":true},{"date":"2022-12-31","value":75.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 56.59M | 63.38M | 97.05M | 139.99M | 150.34M | [{"date":"2019-12-31","value":37.64,"profit":true},{"date":"2020-12-31","value":42.16,"profit":true},{"date":"2021-12-31","value":64.55,"profit":true},{"date":"2022-12-31","value":93.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 324.25M | 476.72M | 604.84M | 793.02M | 1.09B | [{"date":"2019-12-31","value":29.67,"profit":true},{"date":"2020-12-31","value":43.62,"profit":true},{"date":"2021-12-31","value":55.34,"profit":true},{"date":"2022-12-31","value":72.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 85.14% | 88.26% | 86.17% | 85.00% | 87.91% | [{"date":"2019-12-31","value":96.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.63,"profit":true},{"date":"2022-12-31","value":96.3,"profit":true},{"date":"2023-12-31","value":99.6,"profit":true}] |
Operating Expenses | 846.57M | 1.04B | 1.05B | 1.33B | 1.36B | [{"date":"2019-12-31","value":62.21,"profit":true},{"date":"2020-12-31","value":76.49,"profit":true},{"date":"2021-12-31","value":77.49,"profit":true},{"date":"2022-12-31","value":97.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (522.32M) | (564.16M) | (449.71M) | (536.20M) | (267.82M) | [{"date":"2019-12-31","value":-52232300000,"profit":false},{"date":"2020-12-31","value":-56416300000,"profit":false},{"date":"2021-12-31","value":-44971000000,"profit":false},{"date":"2022-12-31","value":-53620100000,"profit":false},{"date":"2023-12-31","value":-26782400000,"profit":false}] |
Total Non-Operating Income/Expense | (214.99M) | (45.88M) | (22.41M) | (190.52M) | (208.08M) | [{"date":"2019-12-31","value":-21498800000,"profit":false},{"date":"2020-12-31","value":-4587900000,"profit":false},{"date":"2021-12-31","value":-2240900000,"profit":false},{"date":"2022-12-31","value":-19052200000,"profit":false},{"date":"2023-12-31","value":-20807900000,"profit":false}] |
Pre-Tax Income | (713.88M) | (553.07M) | (418.95M) | (689.96M) | (520.10M) | [{"date":"2019-12-31","value":-71388000000,"profit":false},{"date":"2020-12-31","value":-55306500000,"profit":false},{"date":"2021-12-31","value":-41894800000,"profit":false},{"date":"2022-12-31","value":-68996300000,"profit":false},{"date":"2023-12-31","value":-52009800000,"profit":false}] |
Income Taxes | 1.20M | 1.06M | (168.00K) | 13.53M | 15.88M | [{"date":"2019-12-31","value":7.53,"profit":true},{"date":"2020-12-31","value":6.69,"profit":true},{"date":"2021-12-31","value":-1.06,"profit":false},{"date":"2022-12-31","value":85.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (715.08M) | (554.13M) | (418.78M) | (703.49M) | (535.98M) | [{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-53597700000,"profit":false}] |
Income From Continuous Operations | (715.08M) | (554.13M) | (418.78M) | (703.49M) | (690.88M) | [{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-69087600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (715.08M) | (554.13M) | (418.78M) | (703.49M) | (535.98M) | [{"date":"2019-12-31","value":-71507500000,"profit":false},{"date":"2020-12-31","value":-55412800000,"profit":false},{"date":"2021-12-31","value":-41878000000,"profit":false},{"date":"2022-12-31","value":-70348800000,"profit":false},{"date":"2023-12-31","value":-53597700000,"profit":false}] |
EPS (Diluted) | (7.32) | (6.49) | (6.01) | (8.03) | (6.12) | [{"date":"2019-12-31","value":-732,"profit":false},{"date":"2020-12-31","value":-649,"profit":false},{"date":"2021-12-31","value":-601,"profit":false},{"date":"2022-12-31","value":-803,"profit":false},{"date":"2023-12-31","value":-612,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SRPT | |
---|---|
Cash Ratio | 1.71 |
Current Ratio | 3.84 |
Quick Ratio | 3.03 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SRPT | |
---|---|
ROA (LTM) | 1.51% |
ROE (LTM) | 12.27% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SRPT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.66 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.34 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SRPT | |
---|---|
Trailing PE | 77.76 |
Forward PE | 9.62 |
P/S (TTM) | 6.93 |
P/B | 9.31 |
Price/FCF | NM |
EV/R | 7.05 |
EV/Ebitda | 61.77 |
PEG | 159.25 |
Sarepta Therapeutics Inc (SRPT) share price today is $118.97
Yes, Indians can buy shares of Sarepta Therapeutics Inc (SRPT) on Vested. To buy Sarepta Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SRPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sarepta Therapeutics Inc (SRPT) via the Vested app. You can start investing in Sarepta Therapeutics Inc (SRPT) with a minimum investment of $1.
You can invest in shares of Sarepta Therapeutics Inc (SRPT) via Vested in three simple steps:
The 52-week high price of Sarepta Therapeutics Inc (SRPT) is $173.25. The 52-week low price of Sarepta Therapeutics Inc (SRPT) is $91.34.
The price-to-earnings (P/E) ratio of Sarepta Therapeutics Inc (SRPT) is 77.5779
The price-to-book (P/B) ratio of Sarepta Therapeutics Inc (SRPT) is 9.31
The dividend yield of Sarepta Therapeutics Inc (SRPT) is 0.00%
The market capitalization of Sarepta Therapeutics Inc (SRPT) is $11.41B
The stock symbol (or ticker) of Sarepta Therapeutics Inc is SRPT